Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

Theresa Placke, Katrin Faber, Atsushi Nonami, Sarah L. Putwain, Helmut R. Salih, Florian H. Heidel, Alwin Krämer, David E. Root, David A. Barbie, Andrei V. Krivtsov, Scott A. Armstrong, William C. Hahn, Brian J. Huntly, Stephen M. Sykes, Michael D. Milsom, Claudia Scholl, Stefan Fröhling

研究成果: ジャーナルへの寄稿記事

68 引用 (Scopus)

抄録

Chromosomal rearrangements involving the H3K4 methyltransferase mixed-lineage leukemia (MLL) trigger aberrant gene expression in hematopoietic progenitors and give rise to an aggressive subtype of acute myeloid leukemia (AML). Insights into MLL fusionmediated leukemogenesis have not yet translated into better therapies because MLL is difficult to target directly, and the identity of the genes downstream of MLL whose altered transcription mediates leukemic transformation are poorly annotated.We used a functional genetic approach to uncover that AML cells driven by MLL-AF9 are exceptionally reliant on the cell-cycle regulator CDK6, but not its functional homolog CDK4, and that the preferential growth inhibition induced by CDK6 depletion is mediated through enhanced myeloid differentiation. CDK6 essentiality is also evident in AML cells harboring alternate MLL fusions and a mouse model of MLL-AF9-driven leukemia and can be ascribed to transcriptional activation of CDK6 by mutant MLL. Importantly, the context-dependent effectsof loweringCDK6expressionarecloselyphenocopiedbya small-moleculeCDK6inhibitor currently in clinicaldevelopment.These data identify CDK6 as critical effector of MLL fusions in leukemogenesis that might be targeted to overcome the differentiation block associated with MLL-rearranged AML, and underscore that cell-cycle regulators may have distinct, noncanonical, and nonredundant functions in different contexts.

元の言語英語
ページ(範囲)13-23
ページ数11
ジャーナルBlood
124
発行部数1
DOI
出版物ステータス出版済み - 7 3 2014

Fingerprint

Acute Myeloid Leukemia
Leukemia
Fusion reactions
Cells
Methyltransferases
Transcription
Gene expression
Genes
Chemical activation
Myeloid Cells
Cell Cycle
Transcriptional Activation
Gene Expression

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

これを引用

Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., ... Fröhling, S. (2014). Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood, 124(1), 13-23. https://doi.org/10.1182/blood-2014-02-558114

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. / Placke, Theresa; Faber, Katrin; Nonami, Atsushi; Putwain, Sarah L.; Salih, Helmut R.; Heidel, Florian H.; Krämer, Alwin; Root, David E.; Barbie, David A.; Krivtsov, Andrei V.; Armstrong, Scott A.; Hahn, William C.; Huntly, Brian J.; Sykes, Stephen M.; Milsom, Michael D.; Scholl, Claudia; Fröhling, Stefan.

:: Blood, 巻 124, 番号 1, 03.07.2014, p. 13-23.

研究成果: ジャーナルへの寄稿記事

Placke, T, Faber, K, Nonami, A, Putwain, SL, Salih, HR, Heidel, FH, Krämer, A, Root, DE, Barbie, DA, Krivtsov, AV, Armstrong, SA, Hahn, WC, Huntly, BJ, Sykes, SM, Milsom, MD, Scholl, C & Fröhling, S 2014, 'Requirement for CDK6 in MLL-rearranged acute myeloid leukemia', Blood, 巻. 124, 番号 1, pp. 13-23. https://doi.org/10.1182/blood-2014-02-558114
Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH その他. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014 7 3;124(1):13-23. https://doi.org/10.1182/blood-2014-02-558114
Placke, Theresa ; Faber, Katrin ; Nonami, Atsushi ; Putwain, Sarah L. ; Salih, Helmut R. ; Heidel, Florian H. ; Krämer, Alwin ; Root, David E. ; Barbie, David A. ; Krivtsov, Andrei V. ; Armstrong, Scott A. ; Hahn, William C. ; Huntly, Brian J. ; Sykes, Stephen M. ; Milsom, Michael D. ; Scholl, Claudia ; Fröhling, Stefan. / Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. :: Blood. 2014 ; 巻 124, 番号 1. pp. 13-23.
@article{43154d75e04b4ed39b0a5157f1a6a797,
title = "Requirement for CDK6 in MLL-rearranged acute myeloid leukemia",
abstract = "Chromosomal rearrangements involving the H3K4 methyltransferase mixed-lineage leukemia (MLL) trigger aberrant gene expression in hematopoietic progenitors and give rise to an aggressive subtype of acute myeloid leukemia (AML). Insights into MLL fusionmediated leukemogenesis have not yet translated into better therapies because MLL is difficult to target directly, and the identity of the genes downstream of MLL whose altered transcription mediates leukemic transformation are poorly annotated.We used a functional genetic approach to uncover that AML cells driven by MLL-AF9 are exceptionally reliant on the cell-cycle regulator CDK6, but not its functional homolog CDK4, and that the preferential growth inhibition induced by CDK6 depletion is mediated through enhanced myeloid differentiation. CDK6 essentiality is also evident in AML cells harboring alternate MLL fusions and a mouse model of MLL-AF9-driven leukemia and can be ascribed to transcriptional activation of CDK6 by mutant MLL. Importantly, the context-dependent effectsof loweringCDK6expressionarecloselyphenocopiedbya small-moleculeCDK6inhibitor currently in clinicaldevelopment.These data identify CDK6 as critical effector of MLL fusions in leukemogenesis that might be targeted to overcome the differentiation block associated with MLL-rearranged AML, and underscore that cell-cycle regulators may have distinct, noncanonical, and nonredundant functions in different contexts.",
author = "Theresa Placke and Katrin Faber and Atsushi Nonami and Putwain, {Sarah L.} and Salih, {Helmut R.} and Heidel, {Florian H.} and Alwin Kr{\"a}mer and Root, {David E.} and Barbie, {David A.} and Krivtsov, {Andrei V.} and Armstrong, {Scott A.} and Hahn, {William C.} and Huntly, {Brian J.} and Sykes, {Stephen M.} and Milsom, {Michael D.} and Claudia Scholl and Stefan Fr{\"o}hling",
year = "2014",
month = "7",
day = "3",
doi = "10.1182/blood-2014-02-558114",
language = "English",
volume = "124",
pages = "13--23",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

AU - Placke, Theresa

AU - Faber, Katrin

AU - Nonami, Atsushi

AU - Putwain, Sarah L.

AU - Salih, Helmut R.

AU - Heidel, Florian H.

AU - Krämer, Alwin

AU - Root, David E.

AU - Barbie, David A.

AU - Krivtsov, Andrei V.

AU - Armstrong, Scott A.

AU - Hahn, William C.

AU - Huntly, Brian J.

AU - Sykes, Stephen M.

AU - Milsom, Michael D.

AU - Scholl, Claudia

AU - Fröhling, Stefan

PY - 2014/7/3

Y1 - 2014/7/3

N2 - Chromosomal rearrangements involving the H3K4 methyltransferase mixed-lineage leukemia (MLL) trigger aberrant gene expression in hematopoietic progenitors and give rise to an aggressive subtype of acute myeloid leukemia (AML). Insights into MLL fusionmediated leukemogenesis have not yet translated into better therapies because MLL is difficult to target directly, and the identity of the genes downstream of MLL whose altered transcription mediates leukemic transformation are poorly annotated.We used a functional genetic approach to uncover that AML cells driven by MLL-AF9 are exceptionally reliant on the cell-cycle regulator CDK6, but not its functional homolog CDK4, and that the preferential growth inhibition induced by CDK6 depletion is mediated through enhanced myeloid differentiation. CDK6 essentiality is also evident in AML cells harboring alternate MLL fusions and a mouse model of MLL-AF9-driven leukemia and can be ascribed to transcriptional activation of CDK6 by mutant MLL. Importantly, the context-dependent effectsof loweringCDK6expressionarecloselyphenocopiedbya small-moleculeCDK6inhibitor currently in clinicaldevelopment.These data identify CDK6 as critical effector of MLL fusions in leukemogenesis that might be targeted to overcome the differentiation block associated with MLL-rearranged AML, and underscore that cell-cycle regulators may have distinct, noncanonical, and nonredundant functions in different contexts.

AB - Chromosomal rearrangements involving the H3K4 methyltransferase mixed-lineage leukemia (MLL) trigger aberrant gene expression in hematopoietic progenitors and give rise to an aggressive subtype of acute myeloid leukemia (AML). Insights into MLL fusionmediated leukemogenesis have not yet translated into better therapies because MLL is difficult to target directly, and the identity of the genes downstream of MLL whose altered transcription mediates leukemic transformation are poorly annotated.We used a functional genetic approach to uncover that AML cells driven by MLL-AF9 are exceptionally reliant on the cell-cycle regulator CDK6, but not its functional homolog CDK4, and that the preferential growth inhibition induced by CDK6 depletion is mediated through enhanced myeloid differentiation. CDK6 essentiality is also evident in AML cells harboring alternate MLL fusions and a mouse model of MLL-AF9-driven leukemia and can be ascribed to transcriptional activation of CDK6 by mutant MLL. Importantly, the context-dependent effectsof loweringCDK6expressionarecloselyphenocopiedbya small-moleculeCDK6inhibitor currently in clinicaldevelopment.These data identify CDK6 as critical effector of MLL fusions in leukemogenesis that might be targeted to overcome the differentiation block associated with MLL-rearranged AML, and underscore that cell-cycle regulators may have distinct, noncanonical, and nonredundant functions in different contexts.

UR - http://www.scopus.com/inward/record.url?scp=84903954701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903954701&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-02-558114

DO - 10.1182/blood-2014-02-558114

M3 - Article

C2 - 24764564

AN - SCOPUS:84903954701

VL - 124

SP - 13

EP - 23

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -